Allogene Therapeutics Stock Quote ALLO - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.7907

Bid

1.78

Ask

1.90

Volume

2,584,019

1.78 Day's Range 2.00

1.78 52 Week Range 5.775

Market Cap

375.46M

Previous Close

1.92

Open

1.94

Last Trade

1.8199

Last Trade Time

Financial Volume

$ 4,887,084

VWAP

1.8913

Average Volume (3m)

2,692,334

Shares Outstanding

209,672,091

Dividend Yield

PE Ratio

-1.15

Earnings Per Share (EPS)

-1.56

Revenue

95k

Net Profit

-327.27M

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple all... Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.allogene.com

Headquarters

Wilmington, Delaware, USA

Founded

Allogene Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALLO. The last closing price for Allogene Therapeutics was $1.92. Over the last year, Allogene Therapeutics shares have traded in a share price range of $ 1.78 to $ 5.775.

Allogene Therapeutics currently has 209,672,091 shares outstanding. The market capitalization of Allogene Therapeutics is $402.57 million. Allogene Therapeutics has a price to earnings ratio (PE ratio) of -1.15.

Form 8-K - Current report

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

Form 4 - Statement of changes in beneficial ownership of securities

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease IndicationsInnovative Dagger®...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0793	-4.24064171123	1.87	2.11	1.79	2287447	1.91482999	CS
4	-0.4291	-19.3305703217	2.2198	2.405	1.78	2803575	2.00424522	CS
12	-1.2793	-41.671009772	3.07	3.26	1.78	2692334	2.16438322	CS
26	-1.2093	-40.31	3	3.3599	1.78	2262402	2.42656513	CS
52	-1.8093	-50.2583333333	3.6	5.775	1.78	2425638	2.94401488	CS
156	-8.8993	-83.2488306829	10.69	17.49	1.78	2193020	5.42046383	CS
260	-20.1893	-91.8530482257	21.98	55	1.78	1748471	10.76538688	CS

ALLO - Frequently Asked Questions (FAQ)

What is the current Allogene Therapeutics share price?

The current share price of Allogene Therapeutics is $ 1.7907

How many Allogene Therapeutics shares are in issue?

Allogene Therapeutics has 209,672,091 shares in issue

What is the market cap of Allogene Therapeutics?

The market capitalisation of Allogene Therapeutics is USD 402.57M

What is the 1 year trading range for Allogene Therapeutics share price?

Allogene Therapeutics has traded in the range of $ 1.78 to $ 5.775 during the past year

What is the PE ratio of Allogene Therapeutics?

The price to earnings ratio of Allogene Therapeutics is -1.15

What is the cash to sales ratio of Allogene Therapeutics?

The cash to sales ratio of Allogene Therapeutics is 3.6k

What is the reporting currency for Allogene Therapeutics?

Allogene Therapeutics reports financial results in USD

What is the latest annual turnover for Allogene Therapeutics?

The latest annual turnover of Allogene Therapeutics is USD 95k

What is the latest annual profit for Allogene Therapeutics?

The latest annual profit of Allogene Therapeutics is USD -327.27M

What is the registered address of Allogene Therapeutics?

The registered address for Allogene Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Allogene Therapeutics website address?

The website address for Allogene Therapeutics is www.allogene.com

Which industry sector does Allogene Therapeutics operate in?

Allogene Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCTMTCTM Kids IT Education Inc	$ 0.764 (321.87%)	729.72M
REBNReborn Coffee Inc	$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	$ 1.54 (56.50%)	13.82M
CYCNCyclerion Therapeutics Inc	$ 3.92 (54.33%)	82.39M
ENVBEnveric Biosciences Inc	$ 2.0899 (-46.41%)	1.57M
NIVFNewGenIvf Group Ltd	$ 0.1489 (-42.51%)	14.8M
GLSTGlobal Star Acquisition Inc	$ 8.83 (-39.10%)	23.89k
PRPHProPhase Labs Inc	$ 0.2633 (-38.02%)	872.46k
SPGCSacks Parente Golf Inc	$ 0.5601 (-37.86%)	7.27M
TCTMTCTM Kids IT Education Inc	$ 0.764 (321.87%)	731.1M
NVDANVIDIA Corporation	$ 120.07 (-3.67%)	388.5M
RIMEAlgorhythm Holdings Inc	$ 0.02565 (5.12%)	341.8M
CLEUChina Liberal Education Holdings Ltd	$ 0.1938 (30.77%)	237.15M
BHATBlue Hat Interactive Entertainment Technology	$ 0.0355 (-11.25%)	236.44M